48-year-old woman with recurrent ductal carcinoma in situ (DCIS) in left breast

 

48-year-old woman with recurrent ductal carcinoma in situ (DCIS) in left breast. A. Mammographic magnification view shows grouped calcifications in left breast (circle). Stereotactic biopsy yielded grade 2 DCIS. Patient underwent lumpectomy with tumor-negative surgical margins and radiation therapy. B. Mammographic magnification view obtained 4 years after diagnosis shows new calcifications at surgical site (circle). Stereotactic biopsy was performed, which revealed recurrent grade 2 DCIS. Patient then underwent mastectomy.


December 26, 2023 — Results published in the American Journal of Roentgenology (AJR) support mammographic surveillance protocol for patients with a previous breast cancer diagnosis of returning immediately to digital breast tomosynthesis (DBT) screening.

“Although the abnormal interpretation rate (AIR) was higher during the year after diagnosis compared to subsequent years, the AIR remained acceptably low (< 10%) in all years,” concluded lead investigator Dan Do, BA, from Massachusetts General Hospital in Boston.  

This AJR accepted manuscript included 8,090 patients (mean age, 65 years) with a prior breast cancer diagnosis who underwent 30,812 screening DBT examinations during Do et al.’s study period. The cancer detection rate (CDR) was 8.6 per 1,000 examinations, AIR was 5.7%, PPV 1 was 15.1%, sensitivity was 80.3%, specificity was 95.1%, and false-negative rate was 2.1%.

Ultimately, CDR showed a significant independent positive association with years since breast cancer diagnosis (adjusted OR 1.03, 95% CI 1.01-1.05, p<.001). Meanwhile, AIR evidenced significant independent negative association with years since breast cancer diagnosis (adjusted OR 0.99, 95% CI 0.98-1.00, p=.01)—being highest less than or equal to 1 year after diagnosis (7.5%) and lowest greater than 5, but less than 6 years postdiagnosis (5.0%).

For more information: www.arrs.org


Related Content

News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
Subscribe Now